QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial

Kenneth Egstrup, Lennart Bergfeldt, Tibor Duris, Lars Gullestad, Marek Kochmanski, Barbara Kuśnierz, Tonny Nielsen, Stefan Sawicki, Maria Aunes-Jansson, Nils Edvardsson, Lars Frison, Susanne Johansson, Anders Berggren

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Abstrakt

    AZD1305 is an investigational antiarrhythmic agent that prolongs refractoriness through combined potassium and sodium channel inhibition. This study aimed to explore the utility of a test dose in predicting QT interval corrected according to Fridericia's formula (QTcF) during subsequent maintenance treatment with AZD1305.
    OriginalsprogEngelsk
    TidsskriftAmerican Journal of Cardiovascular Drugs
    Vol/bind11
    Udgave nummer3
    Sider (fra-til)199-208
    Antal sider10
    ISSN1175-3277
    DOI
    StatusUdgivet - 1. jun. 2011

      Fingerprint

    Citationsformater

    Egstrup, K., Bergfeldt, L., Duris, T., Gullestad, L., Kochmanski, M., Kuśnierz, B., Nielsen, T., Sawicki, S., Aunes-Jansson, M., Edvardsson, N., Frison, L., Johansson, S., & Berggren, A. (2011). QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs, 11(3), 199-208. https://doi.org/10.2165/11591750-000000000-00000